Literature DB >> 31650964

Effectiveness of the diagnostic pathway of BLES: could it be safely used as a therapeutic method in selected benign lesions?

Tuğba İlkem Kurtoğlu Özçağlayan1, Sibel Özkan Gürdal2, Meltem Öznur3, Ömer Özçağlayan1, Mücahit Doğru1, Birol Topçu4.   

Abstract

PURPOSE: In this study, we aimed to investigate the breast lesion excision system (BLES) as a tool and a practical alternative technique to surgical biopsy and other percutaneous biopsy methods for suspicious lesions. We also wanted to share our initial experience with BLES and compare it with standard percutaneous biopsy methods.
METHODS: From July 2015 to December 2016, a total of 50 patients who had high-risk lesions which were diagnosed with core needle biopsy (CNB) or had lesions with radiology pathology discordance, or had high-risk factors, high-grade anxiety, or suspicious follow-up lesions were enrolled in the study. These lesions were classified as Breast Imaging Reporting and Data System (BI-RADS) 3 or 4, which are under 2 cm. Pathologic diagnoses before and after BLES were evaluated comparatively. The diagnostic and therapeutic success and the complications of CNB and BLES were analyzed.
RESULTS: After BLES, two cases were diagnosed as atypical lobular hyperplasia and atypical ductal hyperplasia. Since the surgical margin was negative, re-excision was not required. Two cases were diagnosed as malignant, and no residual tissue was detected in the operation region. Total excision rates were reported as 56%. Minor hematoma was observed in only 1 out of 50 cases (2%), and spontaneous remission was observed. Two patients (4%) complained of pain during the procedure. Radiofrequency-related thermal damage to the specimen showed: Grade 0 (<0.5 mm) damage in 88%, Grade 1 (0.5-1.5 mm) in 10%, Grade 2 (>1.5 mm or thermal damage in diffuse areas) in 2%, and Grade 3 (diffuse thermal damage or inability to diagnose) in 0%. We found a significant positive correlation between classification of thermal damage and lesion fat cell content (r = 0.345, P = 0.015).
CONCLUSION: BLES is a safe technique that can be effectively used with low complication rates in the excision of benign and high-risk breast lesions in selected cases. It may also provide high diagnostic success and even serve as a therapeutic method in high-risk lesions, such as radial scar, papilloma, and atypical lobular hyperplasia with high complete excision rates without fragmentation of lesions.

Entities:  

Mesh:

Year:  2019        PMID: 31650964      PMCID: PMC6837293          DOI: 10.5152/dir.2019.18427

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  23 in total

1.  Performance and role of the breast lesion excision system (BLES) in small clusters of suspicious microcalcifications.

Authors:  Gianfranco Scaperrotta; Claudio Ferranti; Emanuela Capalbo; Biagio Paolini; Monica Marchesini; Laura Suman; Cristina Folini; Luigi Mariani; Pietro Panizza
Journal:  Eur J Radiol       Date:  2015-11-04       Impact factor: 3.528

2.  Multicenter evaluation of the breast lesion excision system, a percutaneous, vacuum-assisted, intact-specimen breast biopsy device.

Authors:  Angela Sie; David C Bryan; Victor Gaines; Larry K Killebrew; Christine H Kim; Carrie C Morrison; William R Poller; Ada P Romilly; Kathy Schilling; Janet H Sung
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

3.  Stereotactic breast biopsy: improved tissue harvesting with the Mammotome.

Authors:  F Burbank; S H Parker; T J Fogarty
Journal:  Am Surg       Date:  1996-09       Impact factor: 0.688

4.  Nonpalpable breast lesions: correlation of stereotaxic large-core needle biopsy and surgical biopsy results.

Authors:  E L Elvecrog; M C Lechner; M T Nelson
Journal:  Radiology       Date:  1993-08       Impact factor: 11.105

5.  Predictive factors for complete excision and underestimation of one-pass en bloc excision of non-palpable breast lesions with the Intact(®) breast lesion excision system.

Authors:  Jean-Yves Seror; Bénédicte Lesieur; Birgit Scheuer-Niro; Laurent Zerat; Roman Rouzier; Serge Uzan
Journal:  Eur J Radiol       Date:  2011-02-09       Impact factor: 3.528

6.  Ultrasound-guided, vacuum-assisted, percutaneous excision of breast lesions: an accurate technique in the diagnosis of atypical ductal hyperplasia.

Authors:  Ian Grady; Heidi Gorsuch; Shelly Wilburn-Bailey
Journal:  J Am Coll Surg       Date:  2005-07       Impact factor: 6.113

7.  Comparison of the diagnostic accuracy of a vacuum-assisted percutaneous intact specimen sampling device to a vacuum-assisted core needle sampling device for breast biopsy: initial experience.

Authors:  Larry K Killebrew; Ruth H Oneson
Journal:  Breast J       Date:  2006 Jul-Aug       Impact factor: 2.431

8.  The radiological excision of high risk and malignant lesions using the INTACT breast lesion excision system. A case series with an imaging follow up of at least 5 years.

Authors:  S D Allen; P Osin; A Nerurkar
Journal:  Eur J Surg Oncol       Date:  2014-04-02       Impact factor: 4.424

9.  The Intact® breast lesion excision system as a therapeutic device for selected benign breast lesions.

Authors:  Miri Sklair-Levy; Shlomi Rayman; Ady Yosepovich; Andrew Zbar; David Goitein; Douglas Zippel
Journal:  Breast J       Date:  2017-10-11       Impact factor: 2.431

10.  Radiofrequency-assisted intact specimen biopsy of breast tumors: critical evaluation according to the IDEAL recommendations.

Authors:  Suzanne C E Diepstraten; Helena M Verkooijen; Paul J van Diest; Wouter B Veldhuis; Arancha M Fernandez-Gallardo; Katya M Duvivier; Arjen J Witkamp; Thijs van Dalen; Willem P Th M Mali; Maurice A A J van den Bosch
Journal:  Cancer Imaging       Date:  2011-12-28       Impact factor: 3.909

View more
  1 in total

1.  Minimally Invasive Excision of Breast Masses under Ultrasound Guidance: A Single Center's Five-Year Experience on the Breast Lesion Excision System.

Authors:  Hakki Muammer Karakas; Gulsah Yildirim
Journal:  Breast J       Date:  2022-02-04       Impact factor: 2.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.